References
- 1. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, Antunes MJ, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33( 19):2451-96.
- 2. Kamenova Z, Grigorov M, Ingeliev M, Petrova G, Pesheva B. [Correlation between degenerative aortic stenosis and coronary disease], Medlnfo. 2012;4(9):22-6. Bulgarian.
- 3. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med. 2000;343(9):611-7.
- 4. Trayanov I. [Aortic stenosis and aortic regurgitation], Cardio D. 2007;4(2):34-41. Bulgarian.
- 5. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999;341(3): 142-7.
- 6. Cosmi JE, Kort S, Tunick PA, Rosenzweig BP, Freedberg RS, Katz ES, et al. The risk of the development of aortic stenosis in patients with “benign” aortic valve thickening. Arch Intern Med. 2002; 162(20):2345-7.
- 7. Carabello B, Paulus W. Aortic stenosis. Lancet. 2009;373(9667):956-66.
- 8. Koleva K, Zlatareva N, Gudev A. [A new look at degenerative aortic stenosis], MP - SSZ. 2007;38(4): 14-9. Bulgarian.
- 9. Hughes B, Chhoud G, Mehta JL. Aortic stenosis: is it simply a degenerative process or an active atherosclerotic process? Clin Cardiol. 2005;28(3):111-4.
- 10. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein (a) as| a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-53.
- 11. Clarke R, Peden F, Hopewell C, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361 (26):2518-28.
- 12. Bozbas H, Yildirir A, Atar I, Pirat B, Eroglu S, Aydinalp A, et al. Effects of serum levels of novel atherosclerotic risk factors on aortic valve calcification. J Heart Valve Dis. 2007;16(4):387-93.
- 13. Parolari A, Loardi C, Mussoni L, Cavallotti L, Camera M, Biglioli P, et al. Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention. Eur J Cardiothorac Surg. 2009;35(3):493-504.
- 14. De Vecchis R, Di Biase G, Esposito C, Ciccarelli A, Cioppa C, Giasi A, et al. Statin use for nonrheumatic calcific aortic valve stenosis: a review with meta-analysis. J Cardiovasc Med. 2013;14(8):559-67.he development of aortic stenosis in patients with “benign” aortic valve thickening. Arch Intern Med. 2002;162(20):2345-7.
- 15. Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503-12.
- 16. Psaty BM, O’Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JI, et al. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet. 2009;2(l):73-80.
- 17. Gotoh T, Kuroda T, Yamasawa M, Nishinaga M, Mitsuhashi T, Seino Y, et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol. 1995;76(12):928-32.
- 18. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol. 1997;29(3):630-4.
- 19. O’Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vase Biol. 1996; 16(4):523-32.
- 20. Gladera CA, Birgander LS, Soderberg S , Ildgruben HP, Saikku P, Waldenstrom A, et al. Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis. Eur Heart J. 2003;24:198-08.
- 21. Thanassoulis G, Massaro JM, Cury R, Manders E, Benjamin EJ, Vasan RS, et al. Associations of long-term and early adult atherosclerosis risk factors with aortic and mitral valve calcium. J Am Coll Cardiol. 2010;55(22):2491 -8.
- 22. Kutikhin AG, Yuzhalin AE, Brusina EB, Ponasenko AV, Golovkin AS, Barbarash OL. Genetic predisposition to calcific aortic stenosis and mitral annular calcification. Mol Biol Rep. 2014;41(9):5645-63.
- 23. Ortlepp JR, Schmitz F, Mevissen V, Weiss S, Huster J, Dronskowski R, et al. The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis. Eur Heart J. 2004;25(6):514-22.
- 24. Gaudreault N, Ducharme V, Lamontagne M, Guauque-Olarte S, Mathieu P, Pibarot P, et al. Replication of genetic association studies in aortic stenosis in adults. Am J Cardiol. 2011;108(9):1305-10.
- 25. Owens DS, Katz R, Johnson E, Shavelle DM, Probstfield JL, Takasu J, et al. Interaction of age with lipoproteins as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis. Arch Intern Med. 2008; 168(11): 1200-7.
- 26. Kronenberg F, Utermann G. Lipoprotein(a): Resurrected by genetics. J Intern Med. 2013;273( l):6-30.
- 27. Koschinsky L. Novel insights into Lp(a) physiology and pathogenicity: more questions than answers? Cardiovasc Hematol Disord Drug Targets. 2006;6(4):267-78.
- 28. Kamstrup R, Tybjserg-llansen A, Nordestgaard G. Lipoprotein(a) and risk of myocardial infarction-genetic epidemiologic evidence of causality. Scand J Clin Lab Invest. 2011 ;71(2):87-93.
- 29. Berg K. A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand. 1963;59:369-82.
- 30. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330(6144): 132-7.
- 31. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 1987;80(2):458-65.
- 32. Patthy L, Trexler M, Banyai L, Varadi A, Vali Z. Kringles: modules specialized for protein binding. Homology of the gelatin-binding region of fibronectin with the kringle structures of proteases. FEBS Lett. 1984; 171 (1): 131 -6.
- 33. Atkinson RA, Williams RJ. Solution structure of the kringle 4 domain from human plasminogen by 1H nuclear magnetic resonance spectroscopy and distance geometry. J Mol Biol. 1990;212(3):541 -52.
- 34. Knight BL, Perombelon YF, Soutar AK, Wade DR Seed M. Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects. Atherosclerosis. 1991 ;87(2-3):227-37.
- 35. Albers JJ, Koschinsky ML, Marcovina SM. Evidence mounts for a role of the kidney in lipoprotein(a) catabolism. Kidney Int. 2007 ;71 (10):961 -2.
- 36. Rath M, Pauling L. A unified theory of human cardiovascular disease leading the way to the abolition of this disease as a cause for human mortality. J Orthomol Med. 1992;7( 1 ):5-15.
- 37. Sotiriou SN, Orlova VV, Al-Fakhri N, lhanus E, Economopoulou M, Isermann B, et al. Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J. 2006;20(3):559-61.